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Abstract: Herein are highlights from National Lung Cancer Part-
nership’s Annual Meeting, held May 30, 2008 in Chicago. Aiming
to improve the match between lung cancer patients and their drug
treatments, speakers described potential predictive and prognostic
biomarkers. Approaches included: (1) in non-small cell lung cancer,
testing for predictive links between tumor expression levels of DNA
synthesis (RRM1) and repair (ERCC1) enzymes and response to
gemcitabine and cisplatin respectively, and looking for a prognostic
link with ERCC1 expression; (2) validating a predictive “meta-gene
profile” from gene expression microarray studies to distinguish
drug-responsive from unresponsive lung cancer tumors; and (3)
developing proteomics profiling to distinguish lung cancer patients,
including squamous and nonsquamous cell carcinoma patients, who
respond to epidermal growth factor receptor tyrosine kinase inhib-
itors from those who do not. The notion that cancer stem cells are
fundamental in the development and progression of solid tumors
including lung cancers was also discussed. Potential strategies for
using this information to identify useful targets for next-generation
therapies were suggested.
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REPORT
Many new drug treatments for lung cancer show variable
results in terms of efficacy, safety, or both, prompting re-
searchers to seek better ways to match patients with treat-
ments. The 2008 Annual Meeting of the National Lung
Cancer Partnership featured presentations about the progress
and promise of research to address those issues. A panel of
speakers discussed “personalizing medicine” through better
prognostic and predictive methods for the use of lung cancer
treatments, through single gene expression data, complex
gene expression patterns, and protein profiles from blood and
tissues. Stem cell involvement in cancer development and
progression was also described, including how cancer stem
cells may point to new targets for drug therapy.
Panel Discussion: Personalized Therapy—Fact
or Fiction?
Chairing the panel discussion “Personalized Therapy:
Fact or Fiction?,” Frances Shepherd, (Princess Margaret Hos-
pital, Toronto) noted that “a prognostic factor determines the
effect of the tumor on the patient, whereas a predictive factor
determines the effect of the treatment on the tumor.” Thus, a
beneficial prognostic factor “identifies a better outcome re-
gardless of treatment, while a beneficial predictive factor
identifies better outcome from treatment.”
Currently, researchers often look for prognostic or
predictive biomarkers in retrospective analyses of already
completed studies. Frequently, such studies escape statistical
scrutiny when they test new hypotheses post hoc. Shepherd
cautioned to accept only retrospective studies that report
interaction p-values.
Molecular Approaches to Personalized
Medicine: A Focus on DNA Synthesis and
Repair
Chemotherapy for non-small cell lung cancer (NSCLC)
usually involves treatment with 2 drug classes, yielding an
improvement in outcome of approximately 50% compared
with best supportive care. Gerold Bepler (Moffitt Cancer
Center) is testing the idea that current drugs could be better
matched to lung cancer patients through the use of gene
expression profiling of tumors.
Bepler studied expression profiles of two DNA synthe-
sis and repair proteins; ribonucleotide reductase subunit M1
(RRM1) and excision repair cross complementation group 1
(ERCC1) enzyme.1 He found that the levels of both proteins
inversely correlate with favorable chemotherapy responses.
Elevated RRM1 expression may be the dominant determinant
for poor response to gemcitabine,2 whereas patients with
elevated ERCC1 responded poorly to cisplatin.1 In fact,
patients with high ERCC1 levels did worse with cisplatin
than similar patients who went untreated. In general, ERCC1
levels may influence response to platinum-based agents.3
The researchers are asking whether using RRM1 and
ERCC1 levels as predictors improves treatment outcomes
through an ongoing phase III study (NCT00499109). Since
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RRM1 and ERCC1 may each be a predictive marker, the
results of this trial are eagerly awaited.
Improving Prognostic and Predictive Powers
With Gene Expression Microarrays
Lung cancer patients with small tumors (3 cm) typi-
cally receive surgery alone. Anil Potti (Duke University)
noted that 25 to 30% of such patients suffer recurrence, which
is often fatal. Looking for better prognostic indicators than
tumor size, Potti et al. are assessing whether quantitative
analysis of gene expression data from tumors can differenti-
ate relapsed patients from those without recurrence. Accord-
ingly, the investigators retrospectively studied tumors from
patients with small tumors, comparing specimens from indi-
viduals who remained disease-free for 5 years and those
whose cancer returned within 2 years. The researchers iden-
tified several dozen genes whose expression levels, when
combined into a “metagene profile,” distinguished the two
patient groups. The profiling method was validated using
known outcomes, showing that the method classified patients
as likely or not likely to recur with 72% accuracy.4
Next, Potti’s group applied metagene profiling predic-
tively, looking for best fit between existing chemotherapies
and a tumor’s expression profile. They tested the cytotoxicity
of commonly used cancer drugs on cells from the NCI-60 cell
line. The researchers determined which cell lines were sen-
sitive to each drug, and then used that data to develop
predictive gene expression signatures.5
Potti’s team has tested tumors that were also assayed
for ERCC1 expression levels, permitting a comparison be-
tween the predictive powers of his method versus the method
Bepler described. Both methods did well at distinguishing
between cisplatin responders and nonresponders. According
to Potti, his metagene profiling more accurately predicted
positive chemotherapy responders, whereas Bepler’s method
more accurately identified individuals whose tumors would
not respond, making the two strategies complementary.
Potti’s group is also applying metagene profiling to
better match new agents that target specific oncogenic sig-
naling pathways to the patients who are most likely to
respond to them. First, the researchers determined the met-
agene profile for each of several signaling pathways that go
awry in cancer.6 Using that information, they determined
which signaling pathway was activated in each of several
NCI-60 cell lines, and created corresponding metagene pro-
files. The researchers then tested whether these metagene
profiles predicted which drug would work best against which
cell line. Potti showed that a cell line with a metagene profile
indicating a defect in the rat sarcoma virus oncogenic (Ras)
pathway was sensitive to drugs designed to target that path-
way; he obtained similar results in studying other pathways.
The researchers anticipate incorporating such metagene pro-
filing into future clinical trials.
Pattern Recognition: Using Proteomics for
Minimally Invasive Detection
Drug therapies aimed at epidermal growth factor recep-
tor (EGFR) tyrosine kinase inhibitors (TKIs) greatly benefit
approximately 10% of lung cancer patients. Investigators
originally thought that this drug class would just help patients
whose tumors carried EGFR mutations or amplifications.
However, new results show that individuals without known
EGFR modifications also can benefit.7
David Carbone, (Vanderbilt University) is testing the
hypothesis that lung cancers put telltale proteins into the
blood of their host,8 and these protein arrays differ between
EGRF-TKI responders and nonresponders. Carbone’s team
developed a panel of eight serum proteins whose levels
collectively distinguished EGFR-TKI responders from non-
responders in terms of time to disease progression and sur-
vival time. The researchers then validated the test in a new
population of patients. Additionally, researchers at two sep-
arate institutions using this proteomics method to asses the
same patient population had a 97% concordance of results.
Further data generated from retrospective analysis of several
small EGFR-TKI single-arm trials confirmed the predictive
power of this proteomics test.
Although response to EGFR-TKIs is typically associ-
ated with adenocarcinoma,9 some squamous cell patients also
show favorable response to the drugs.10 Carbone’s proteomic
profiling successfully distinguished between EGFR-TKI re-
sponders and nonresponders in retrospective analyses of
squamous cell lung cancer patients.
Proteomic profiling may also predict which patients
would be harmed by EGFR-TKI treatment. Carbone’s data
showed that patients who received an EGFR-TKI, but were
predicted by his assay not to respond to it, died sooner than
the predicted nonresponders who received chemotherapy.
Therefore, Carbone suggests that future studies designed to
compare EGFR-TKIs and chemotherapy could employ pro-
teomic profiling to keep individuals who might be harmed by
EGFR-TKIs from receiving that treatment.
Carbone’s new studies aim to predict responses to
traditional chemotherapies, in this case analyzing cellular and
tissue proteins rather than serum proteins. First, the investi-
gators determined a proteomic profile that classified cell lines
as sensitive or resistant to carboplatin/paclitaxel. Then, the
researchers gathered tumor data from NSCLC patients with
resected tumors who either received postsurgical adjuvant
therapy or surgery alone. Among patients given postsurgical
adjuvant therapy, those whose tumors were predicted to be
drug sensitive showed strikingly better survival at 90 months
(90%; n  10) than those with tumors predicted to be
drug-resistant (20%; n  15). If a similar, larger ongoing
analysis holds up, clinicians will be closer to optimizing
treatments for some lung cancer patients.
Lung Cancer Stem Cells as Targets for Therapy
John Minna (University of Texas Southwestern Medi-
cal Center; UTSW) suggested that the true culprits in solid
tumors are not the bulk of the tumor cell mass, but rather its
stem cells. Cancer stem cells are hypothesized to be the key
source of metastases, as well as the subset of chemoresistant
and radioresistant cells. Understanding tumor stem cell biol-
ogy may be essential for improving both prognostic and
predictive aspects of clinical oncology, Minna said.
Researchers have started to isolate and characterize
cancer stem cells to determine their contribution to various
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cancers. For example, cancer stem cells seem to better resist
the effects of radiation than nonstem cells (reviewed in11).
For gliomas, this radioresistance is apparently due to the stem
cells selectively expressing elevated levels of DNA repair
enzymes, enabling them to withstand more radiation-induced
DNA damage. Whether a similar selective radioresistance
occurs in lung cancer stem cells is currently being investi-
gated. Clinical studies are investigating the prognostic value
of the percent of stem cells in a tumor mass; several studies
show a direct correlation between high levels of tumor stem
cells and poor prognosis.12,13
Now researchers aim to use molecular characteristics of
tumor stem cells predictively, by assessing whether expres-
sion levels of intracellular signaling pathway components in
intact tumors accurately reflect the expression levels of those
proteins in the stem cell component. If so, screening intact
tumors for the expression levels of some of these signaling
factors could help to predict response to treatments.
Minna ended by discussing his work with Jerry Shay
and Joan Schiller (both at UTSW), aimed at enhancing the
sensitivity of NSCLC stem cells to chemotherapy. The inves-
tigators found that an anti-telomerase agent (GRN163L) de-
creased the amount of clonigenic stem-like cells in culture,
and made carboplatin/paxlitaxel treatment more effective.
Preclinical studies will help to determine the optimal duration
of the anti-telomerase treatment to destroy the tumor stem
cells while doing minimal harm to the patients.
CONCLUSION
National Lung Cancer Partnership’s 2008 Annual
Meeting exemplified the progress that has been achieved in
understanding lung tumor biology, and the promise of a day
when individual patients will be matched to particular ther-
apeutic regimens; this day is on the horizon.
For summaries of other talks at the meeting, see www.
NationalLungCancerPartnership.org.
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